132 related articles for article (PubMed ID: 20857135)
21. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Treiber G; Malfertheiner P
J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
[No Abstract] [Full Text] [Related]
22. Acyclovir therapy in prevention of recurrent herpetic keratitis following penetrating keratoplasty.
Ghosh S; Jhanji V; Lamoureux E; Taylor HR; Vajpayee RB
Am J Ophthalmol; 2008 Feb; 145(2):198-202. PubMed ID: 18222189
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil induced myopathy in a patient with lupus nephritis.
Galindo M; Cabello A; Joven B; Alonso A; Carreira P; Porta J; Ricoy JR; Mateo I; Pablos JL
J Rheumatol; 2005 Jan; 32(1):188-90. PubMed ID: 15630748
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review.
Smith MR; Cooper SC
J Crohns Colitis; 2014 Aug; 8(8):890-7. PubMed ID: 24507162
[TBL] [Abstract][Full Text] [Related]
25. Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone.
Khauli RB; Medawar WA; Habbal AA; Birbari AE; Daouk MM; Abdelnoor AM; Uwaydah M; Rahman Bizri A; Sanjad S; Ayvazian PJ; Lovewell T; Stoff JS; Yang Fan P; Bigwood P; Harland R
Transplant Proc; 2001 Aug; 33(5):2776-7. PubMed ID: 11498156
[No Abstract] [Full Text] [Related]
26. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
[TBL] [Abstract][Full Text] [Related]
27. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study.
Reinhard T; Mayweg S; Sokolovska Y; Seitz B; Mittelviefhaus H; Engelmann K; Voiculescu A; Godehardt E; Sundmacher R
Transpl Int; 2005 Jun; 18(6):703-8. PubMed ID: 15910297
[TBL] [Abstract][Full Text] [Related]
28. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Jacob A; Matiello M; Weinshenker BG; Wingerchuk DM; Lucchinetti C; Shuster E; Carter J; Keegan BM; Kantarci OH; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1128-33. PubMed ID: 19752302
[TBL] [Abstract][Full Text] [Related]
29. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Sankatsing SU; Hoggard PG; Huitema AD; Sparidans RW; Kewn S; Crommentuyn KM; Lange JM; Beijnen JH; Back DJ; Prins JM
Clin Pharmacokinet; 2004; 43(12):823-32. PubMed ID: 15355127
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis.
Yalçindağ FN; Amer R; Forrester JV
J Ocul Pharmacol Ther; 2008 Apr; 24(2):249-54. PubMed ID: 18321200
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil therapy for inflammatory eye disease.
Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
[TBL] [Abstract][Full Text] [Related]
32. Disseminated herpes zoster causing extensive skin necrosis.
Appenzeller S; Vinet E; Clarke A
Lupus; 2009 Apr; 18(5):476. PubMed ID: 19318405
[No Abstract] [Full Text] [Related]
33. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
Chatel MA; Larkin DF
Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
[TBL] [Abstract][Full Text] [Related]
34. Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil.
O'Connor AS; Navab F; Germain MJ; Freeman JK; Mulhern JG; O'Shea MH; Lipkowitz GS; Madden RL; Braden GL
Dig Dis Sci; 2003 Nov; 48(11):2191-5. PubMed ID: 14705827
[No Abstract] [Full Text] [Related]
35. Treatment of atopic dermatitis with mycophenolate mofetil.
Hansen ER; Buus S; Deleuran M; Andersen KE
Br J Dermatol; 2000 Dec; 143(6):1324-6. PubMed ID: 11122047
[No Abstract] [Full Text] [Related]
36. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
37. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
38. Treatment of five haemodynamically stable dogs with immune-mediated thrombocytopenia using mycophenolate mofetil as single agent.
Yau VK; Bianco D
J Small Anim Pract; 2014 Jun; 55(6):330-3. PubMed ID: 24602067
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil.
Grundmann-Kollmann M; Korting HC; Behrens S; Leiter U; Krähn G; Kaufmann R; Peter RU; Kerscher M
Br J Dermatol; 1999 Jul; 141(1):175-6. PubMed ID: 10417549
[No Abstract] [Full Text] [Related]
40. [Reversible posterior leukoencephalopathy induced by tacrolimus in a renal transplant patient].
Izquierdo Pajuelo MJ; Jiménez Delgado JD; Rangel Mayoral JF; Liso Rubio FJ
Farm Hosp; 2009; 33(3):177-8. PubMed ID: 19712604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
